Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Appointed director
Inv. presentation
Midatech Pharma US Inc. (DARA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/02/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Third Quarter 2015 Results Record Revenues for Q3 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – November 2, 2015 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results. Third Quarter 2015 Financial Snapshot DARA reported net revenues of $1.181 million for the third quarter ended September 30, 2015 based on gross product sales in excess of $1.5 million, as compared to net revenues of $597.8 ..."
08/12/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Second Quarter 2015 Results Record Revenues for Q2 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – August 12 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results. Second Quarter 2015 Financial Snapshot DARA reported net revenues of $990.8 thousand for the second quarter ended June 30, 2015 based on gross product sales in excess of $1.4 million, as compared to net revenues of $409.4 thousan..."
05/13/2015 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FIRST QUARTER 2015 RESULTS Company to provide inaugural 2015 revenue guidance based upon continued commercial progress Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its first quarter 2015 results. First Quarter 2015 Financial Snapshot DARA reported net revenues of $652.2 thousand for the first quarter ended March 31, 2015 based on gross product sales in excess of $850 thousand, as compared to net revenues of $161.5 thousand for the first quarter ended March 31, 2014, a year over year increase of 304%. The incre..."
03/03/2015 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 RESULTS Strong Annual Revenue Growth Driven By Execution of Commercial Sales Strategy Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its financial results for the fourth quarter and full year ended December 31, 2014. The Company also provided a business update on its fourth quarter 2014 operational and commercial highlights. Fourth Quarter 2014 Financial Snapshot DARA reported net revenues of $1.89 million for the full year ended December 31, 2014 based on gross product sales of ..."
11/05/2014 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES THIRD QUARTER 2014 RESULTS Continued strong revenue growth driven by sales momentum across broad portfolio Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2014 results. Third Quarter 2014 Financial Snapshot DARA reported net revenues of $597.8 thousand for the third quarter ended September 30, 2014 based on gross product sales in excess of $690 thousand, as compared to net revenues of $138.9 thousand for the third quarter ended September 30, 2013, a year over year increase of 330%. The increase i..."
08/12/2014 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES SECOND QUARTER 2014 RESULTS Record Quarterly Sales Driven By Commercial Success Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2014 results. Second Quarter 2014 Financial Snapshot DARA reported net revenues of $409.4 thousand for the second quarter ended June 30, 2014 based on gross product sales in excess of $500 thousand, as compared to net revenues of approximately $76.9 thousand for the second quarter ended June 30, 2013, a year over year increase of 432%. The increase in revenues was prima..."
05/12/2014 8-K Quarterly results
Docs: "DARA BIOSCIENCES ANNOUNCES FIRST QUARTER 2014 RESULTS Company Implemented New Nationwide Sales Force in January; Complemented Oncology Supportive Care Product Portfolio Raleigh, NC – – DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its first quarter 2014 results. First Quarter 2014 Financial Snapshot For the first quarter ended March 31, 2014, DARA reported a net loss attributable to controlling interest of , or per share as compared to a net loss attributable to controlling interest of , or per share for the first quarter ended March 31, 2013. As of Mar..."
11/14/2013 8-K Investor presentation, Quarterly results
Docs: "DARA REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS AND HIGHLIGHTS COMMERCIAL MOMENTUM ON SYNERGISTIC ONCOLOGY SUPPORTIVE CARE PRODUCT PORTFOLIO -Refined commercial strategy launched Q2 2013 increases sales frequency, raises product awareness and yields encouraging progress across product portfolio fueling significant growth in Q3 revenues- -Recent Alamo and Mission Pharmacal agreements to expand national sales force from 5 to 20 representatives and complement synergistic supportive care products portfolio- -Company poised for robust revenue generation in 2014-",
"SLIDE PRESENTATION"
08/14/2013 8-K Quarterly results
Docs: "DARA REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS AND OPERATIONAL OVERVIEW -Company’s priority remains focusing expertise and resources on commercialization of its oncology treatment and oncology supportive care pharmaceutical products: Soltamox®, Gelclair® and Bionect®-"
11/09/2007 8-K Quarterly results
Docs: "Point Therapeutics Reports Third Quarter 2007 Financial Results"
08/09/2007 8-K Quarterly results
Docs: "Point Therapeutics Reports Second Quarter 2007 Financial Results"
05/15/2007 8-K Quarterly results
Docs: "Point Therapeutics Reports First Quarter 2007 Financial Results"
03/16/2007 8-K Quarterly results
Docs: "Point Therapeutics Reports Fourth Quarter and Year-End 2006 Financial Results"
11/13/2006 8-K Quarterly results
Docs: "Point Therapeutics Reports Third Quarter 2006 Financial Results"
08/09/2006 8-K Quarterly results
Docs: "Point Therapeutics Reports Second Quarter 2006 Financial Results; Conference Call Scheduled for Today"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy